Literature DB >> 17061714

Hyperopic LASIK with Esiris/Schwind technology.

Jorge Alió1, Ahmed Galal, Maria José Ayala, Alberto Artola.   

Abstract

PURPOSE: To investigate the refractive and visual outcomes of hyperopic LASIK using Esiris/Schwind technology.
METHODS: This retrospective non-comparative observational study included 106 eyes (65 patients) operated with the Esiris/Schwind laser for hyperopia. Eyes were divided into two groups: group 1, < or = +3.99 diopters (D) and group 2, > or = +4.0 D (up to +7.0 D). Visual outcome for distance and near uncorrected (UCVA) and best spectacle-corrected visual acuities (BSCVA) (decimal values), cycloplegic refraction, keratometry (K), pachymetry, and complications were evaluated.
RESULTS: In group 1, mean UCVA was 0.4 +/- 0.1 preoperatively and 0.8 +/- 0.2 6 months postoperatively. Mean BSCVA was 0.9 +/- 0.1 preoperatively and 0.9 +/- 0.1 6 months postoperatively. Safety index was 1.1 and efficacy index was 0.97. Mean spherical equivalent refraction was +2.33 +/- 0.9 D preoperatively and +0.3 +/- 0.3 D 6 months postoperatively. Mean K reading was 43.7 +/- 1.1 D preoperatively and 45.0 +/- 1.6 D 6 months postoperatively. In group 2, mean UCVA was 0.3 +/- 0.1 preoperatively and 0.8 +/- 0.2 6 months postoperatively. Mean BSCVA was 0.9 +/- 0.1 preoperatively and 0.9 +/- 0.1 6 months postoperatively. Safety index was 0.98 and efficacy index was 0.92. Mean spherical equivalent refraction was +5.1 +/- 0.9 D preoperatively and +0.4 +/- 0.5 D 6 months postoperatively. Mean K reading was 43.1 +/- 1.6 D preoperatively and 46.0 +/- 1.4 D 6 months postoperatively. Forty-six (90.2%) of 51 eyes in group 1 and 47 (85.5%) of 55 eyes in group 2 were within +/- 0.5 D of emmetropia. At 6-month follow-up, 40 (78%) of 51 eyes in group 1 had UCVA of 20/20 compared to 41 (75%) of 51 eyes in group 2. One (2%) of 51 eyes in group 1 and 4 (7.3%) of 55 eyes in group 2 lost < or = 2 lines of BSCVA. No eye lost >2 lines of BSCVA.
CONCLUSIONS: Hyperopic LASIK with Esiris/Schwind technology is effective and safe in the correction of hyperopia up to + 7.0 D. Although a slight statistical significance was found for low hyperopia, visual and refractive results obtained in high hyperopia were encouraging.

Entities:  

Mesh:

Year:  2006        PMID: 17061714     DOI: 10.3928/1081-597X-20061001-07

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  7 in total

1.  Role of preoperative cycloplegic refraction in LASIK treatment of hyperopia.

Authors:  Andreas Frings; Johannes Steinberg; Vasyl Druchkiv; Stephan J Linke; Toam Katz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-03       Impact factor: 3.117

2.  Long-Term Followup of Laser In Situ Keratomileusis for Hyperopia Using a 213 nm Wavelength Solid-State Laser.

Authors:  Carmina Franz G Quito; Archimedes Lee D Agahan; Raymond P Evangelista
Journal:  ISRN Ophthalmol       Date:  2013-03-03

3.  Assessment of refractive outcome of femtosecond-assisted LASIK for hyperopia correction.

Authors:  Mohamed Tarek El-Naggar; Dikran Gilbert Hovaghimian
Journal:  Electron Physician       Date:  2017-03-25

4.  Corneal Stability following Hyperopic LASIK with Advanced Laser Ablation Profiles Analyzed by a Light Propagation Study.

Authors:  Almutez M Gharaibeh; Asier Villanueva; David Mas; Julian Espinosa; Jorge L Alió
Journal:  J Ophthalmol       Date:  2018-03-28       Impact factor: 1.909

5.  Lasik as a Solution for High Hypermetropia.

Authors:  Alma Biscevic; Ajla Pidro; Melisa Ahmedbegovic Pjano; Senad Grisevic; Nina Ziga; Maja Bohac
Journal:  Med Arch       Date:  2019-06

6.  Femtosecond-LASIK outcomes using the VisuMax®-MEL® 80 platform for hyperopia and hyperopic astigmatism refractive surgery.

Authors:  Bogdana Tăbăcaru; Horia Tudor Stanca; Ruxandra Angela Pîrvulescu; Simona Stanca; Ciprian Danielescu; Mihnea Munteanu; Cosmin Roșca; Adrian Cosmin Teodoru
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

7.  LASIK and PRK in hyperopic astigmatic eyes: is early retreatment advisable?

Authors:  Andreas Frings; Gisbert Richard; Johannes Steinberg; Vasyl Druchkiv; Stephan Johannes Linke; Toam Katz
Journal:  Clin Ophthalmol       Date:  2016-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.